Comparative Pharmacology
Head-to-head clinical analysis: PYLARIFY TRUVU versus TECHNETIUM TC 99M SESTAMIBI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PYLARIFY TRUVU versus TECHNETIUM TC 99M SESTAMIBI.
PYLARIFY TRUVU vs TECHNETIUM TC 99M SESTAMIBI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PYLARIFY is a PSMA-targeted PET imaging agent composed of a urea-based PSMA ligand (piflufolastat) labeled with fluorine-18. It binds to prostate-specific membrane antigen (PSMA) on prostate cancer cells, allowing PET imaging for detection of PSMA-positive lesions.
Technetium Tc 99m sestamibi is a cationic lipophilic complex that passively diffuses across cell membranes and accumulates in mitochondria due to the negative mitochondrial membrane potential. It is used as a myocardial perfusion imaging agent to visualize blood flow to the heart muscle.
1 mg/kg intravenously every 3 months.
Myocardial imaging: 740-1110 MBq (20-30 mCi) IV bolus, single dose. Parathyroid imaging: 740-925 MBq (20-25 mCi) IV bolus, single dose.
None Documented
None Documented
Terminal elimination half-life: approximately 77 hours (range 68-85 hours) in patients with prostate cancer. This supports a 2-week dosing interval for single-photon emission computed tomography (SPECT) imaging.
Terminal elimination half-life: approximately 6 hours (range 4–8 hours) for myocardial clearance. Delayed clearance may occur in patients with hepatic or renal impairment.
Renal excretion: approximately 93% (3% unchanged, 97% as metabolites). Fecal excretion: approximately 5%. Biliary excretion is negligible.
Primarily renal: approximately 33% of injected dose excreted in urine within 8 hours, increasing to about 50% by 24 hours. Hepatic uptake with subsequent biliary excretion accounts for the remainder; fecal elimination is less than 2% of administered dose.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical